Under the DOJ settlement, Novartis and Alcon each entered into a deferred prosecution agreement; Novartis agreed to pay a fine of $225 million and Alcon agreed to pay $8.9 million in criminal penalties. Novartis also entered into a settlement with the SEC under which they agreed to pay a total of $112 million.